Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSGeneric

AKYNZEO

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE

Standard Dose
EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview AKYNZEO is listed in Drugs@FDA under application 210493 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE Form and strength POWDER;INTRAVENOUS - EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL Sponsor HELSINN HLTHCARE Submission history Latest submission status date: 2023-02-15 00:00:00.

Structured Monograph

Clinical summary

Approval overview AKYNZEO is listed in Drugs@FDA under application 210493 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE Form and strength POWDER;INTRAVENOUS - EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL Sponsor HELSINN HLTHCARE Submission history Latest submission status date: 2023-02-15 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.